OncoMatch/Clinical Trials/NCT05141513
Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma
Is NCT05141513 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for pancreatic cancer.
This study is designed to investigate the safety of intraoperative radiation therapy (IORT) in patients with localized pancreatic cancer undergoing surgical resection after neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT).
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage RESECTABLE, BORDERLINE RESECTABLE (BRPC), LOCALLY ADVANCED (LAPC) (NCCN)
Resectable/BRPC/LAPC as defined by NCCN guidelines (Figure 1) as follows confirmed via CT, EUS, or other imaging modalities.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: multi-agent chemotherapy — upfront
Upfront treatment with multi-agent chemotherapy
Cannot have received: thoracic/abdominal radiation therapy
Previous thoracic/abdominal radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Johns Hopkins Hospital · Baltimore, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify